Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Marc Plesseria

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Methods in Enzymology|October 11, 2022
Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samplesMax Meyrath, Martyna Szpakowska, Jean-Marc Plesseria, et al.
Molecular Oncology|August 1, 2019
FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cellsCarole Seguin-Devaux, Jean-Marc Plesseria, Charlène Verschueren, et al.
Journal of Virological Methods|August 23, 2005
A new recombinant virus system for the study of HIV-1 entry and inhibitionFrancois Roman, Wim Ammerlaan, Jean-Marc Plesseria, et al.
Immunotargets and Therapy|September 12, 2025
Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast CancerCarole Seguin-Devaux, Bianca Brandus, Jean-Marc Plesseria, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Methods in Enzymology|October 11, 2022
Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samplesMax Meyrath, Martyna Szpakowska, Jean-Marc Plesseria, et al.
Molecular Oncology|August 1, 2019
FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cellsCarole Seguin-Devaux, Jean-Marc Plesseria, Charlène Verschueren, et al.
Journal of Virological Methods|August 23, 2005
A new recombinant virus system for the study of HIV-1 entry and inhibitionFrancois Roman, Wim Ammerlaan, Jean-Marc Plesseria, et al.
Immunotargets and Therapy|September 12, 2025
Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast CancerCarole Seguin-Devaux, Bianca Brandus, Jean-Marc Plesseria, et al.
Pageof 1